Benralizumab: Effectiveness in Patients with Uncontrolled Severe Eosinophilic Asthma at 6 and 12 Months at a Third-Level Care Hospital. Capacity for ICS-LABA Therapy Reduction
Benralizumab improved respiratory function as well as key biomarkers such as eosinophil count, exhaled nitric oxide fraction (FeNO), which reflected in a decreased requirement of inhaled corticosteroids and improved symptom control.
Authors
- Sergio García-García (ORCID: https://orcid.org/0000-0003-2356-5306)
- Karla Daniela González-Íñiguez (ORCID: https://orcid.org/0000-0002-3796-7093)
- Yair González-Tuyub (ORCID: https://orcid.org/0000-0002-5707-0240)
- Paula Lizarazo-Guiza
Institutions
- AstraZeneca (Brazil) (BR)
- Institute for Social Security and Services for State Workers (MX)
Publication Details
- Journal
- Journal of Asthma and Allergy
- Published
- 2024-11-01
- DOI
- https://doi.org/10.2147/jaa.s472490
- Citations
- 3
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.98
Funders
- AstraZeneca